Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Citi
Chubb
Federal Trade Commission
Express Scripts
Moodys
Medtronic
Deloitte

Generated: May 23, 2018

DrugPatentWatch Database Preview

STADOL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Summary for STADOL
Drug patent expirations by year for STADOL
Medical Subject Heading (MeSH) Categories for STADOL
Synonyms for STADOL
(-)-17-(Cyclobutylmethyl)morphinan-3,14-diol
(-)-butorphanol
(-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0;{1,10}.0;{2,7}]heptadeca-2(7),3,5-triene-4,10-diol
(1S,9R,10S)-17-(CYCLOBUTYLMETHYL)-17-AZATETRACYCLO[7.5.3.0(1),(1)?.0(2),?]HEPTADECA-2(7),3,5-TRIENE-4,10-DIOL
17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
42408-82-2
50807-69-7
58786-99-5
AN-6427
API0009093
BC 2627
BC-2627
BDBM50240437
Beforal
Beforal (TN)
BIDD:GT0549
Butorfanol
Butorfanol [INN-Spanish]
butorphanol
Butorphanol (USAN/INN)
Butorphanol [USAN:BAN:INN]
Butorphanol [USAN:INN:BAN]
Butorphanol tartrate
Butorphanolum
Butorphanolum [INN-Latin]
C-33046
C06863
CHEBI:3242
CHEMBL33986
CTK7J9662
D03197
D0X9RG
DEA No. 9720
dl-3,14-Dihydroxy-N- morphinan
DTXSID1022714
EINECS 255-808-8
FT-0664002
GTPL7591
IFKLAQQSCNILHL-QHAWAJNXSA-N
J-504151
L-3,14-dihydroxy-N-(cyclobutylmethyl)morphinan
l-BC 2627
L-N-Cyclobutylmethyl-3,14-dihydroxymorphinan
levo-BC-2627
LS-91729
Moradol
Moradol (TN)
Morphinan-3,14-diol, 17-(cyclobutylmethyl)-
N-cyclobutylmethyl-3,14-dihydroxymorphinan
PL006230
Q-200770
QV897JC36D
SCHEMBL3749
Stadol NS
UNII-QV897JC36D
ZINC3812988

US Patents and Regulatory Information for STADOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apothecon STADOL butorphanol tartrate INJECTABLE;INJECTION 017857-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Apothecon STADOL PRESERVATIVE FREE butorphanol tartrate INJECTABLE;INJECTION 017857-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb STADOL butorphanol tartrate SPRAY, METERED;NASAL 019890-001 Dec 12, 1991 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Apothecon STADOL PRESERVATIVE FREE butorphanol tartrate INJECTABLE;INJECTION 017857-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
US Department of Justice
US Army
Cantor Fitzgerald
Citi
Fuji
Healthtrust
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.